Moderate Evidence
Research Overview
VK2735 Research for Obesity
An overview of research and source records on VK2735 in the context of obesity.
Research Summary
VK2735 is in Phase 3 development for obesity treatment. VENTURE Phase 2 demonstrated 14.7% weight loss at 13 weeks with subcutaneous administration. The VANQUISH-1 Phase 3 trial (obesity without type 2 diabetes) has enrolled 4,500 patients for a 78-week evaluation and is ongoing.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.